No. 3: Fresenius (medical care segment)
Bad Homburg, Germany
2017 revenues: $20,095,920,000 (€17,784,000,000)
2017 R&D spend: $148,030,000
Fiscal year ending: December 31, 2017
Rice Powell, chairman; Michael Brosnan, CFO; Dr. Olaf Schermeier, CEO for global R&D; Kent Wanzek, CEO for global manufacturing & quality; Bill Valle, CEO for Fresenius Medical Care North America; Harry de Wit, CEO for Fresenius Medical Care Asia-Pacific
The big news from Fresenius Medical Care this year was the same as last year’s: the $2 billion pickup of NxStage Medical that, as of this writing in mid-September 2018, had yet to close. (It’s on track to meet its Nov. 5 deadline, the German hemodialysis giant said in July). Also that month, Fresenius dealt its Sound Inpatient Physicians business for $2.2 billion to an investment consortium led by Summit Partners. But another deal, the $4.3 billion merger with U.S. generic drugmaker Akorn, foundered after Fresenius said its due diligence process uncovered material breaches of FDA data integrity requirements. (The companies later exchanged lawsuits over the spiked deal that are still under way). Fresenius also inked a $150 million deal with Humacyte for the exclusive rights to commercialize the Humacyl bioengineered blood vessel.